Empagliflozin 25 mg (Empagliflozin 2L-Proline)

Adult dose

The recommended dosage of this medication is 10 mg once daily for monotherapy and as an additional combination therapy with insulin or other antihyperglycemic agents. If tolerability to 10 mg is good and additional blood sugar control is necessary, the dosage can be increased to 25 mg once daily. When used in combination with sulfonylureas or insulin, a dosage reduction of sulfonylureas or insulin may be considered to reduce the risk of hypoglycemia.

This medication should not be used in patients who are allergic to the active or inactive ingredients. It should also not be administered to patients with Type 1 diabetes or diabetic ketoacidosis. Patients with impaired kidney function may experience reduced effectiveness of this medication, and kidney function should be monitored regularly. The use of this medication is not recommended in cases of severely impaired kidney function. When used alongside insulin or sulfonylureas, there is a risk of hypoglycemia, and dosage adjustments of those medications may be necessary. During treatment, attention should be paid to symptoms of hypoglycemia, especially when taken with insulin or sulfonylureas. Genital infections or urinary tract infections may occur; if infection symptoms arise, consult a healthcare provider promptly. Reduced fluid volume may lead to low blood pressure, so patients at risk of dehydration or low blood pressure should be cautious. Serious metabolic acidosis called ketoacidosis may occur, so if symptoms such as vomiting, abdominal pain, or difficulty breathing arise, seek medical attention immediately. Elderly patients or those at risk of fluid loss should closely monitor their fluid status, and may pause the medication if needed. It is advisable to avoid use during pregnancy, and the medication should be halted if pregnancy is confirmed. During breastfeeding, it is recommended to avoid this medication and stop breastfeeding. Safety and effectiveness in children have not been established, and use in this population should be avoided. No specific toxic symptoms have been reported in cases of overdose, but appropriate treatment based on clinical condition may be necessary. During treatment, be cautious of hypoglycemia risk while driving or operating machinery. This medication may interact with other drugs, so inform your healthcare provider of any other medications being taken. When storing this medication, keep it out of reach of children and do not transfer to other containers.

Serious side effects

Hives, angioedema, ketoacidosis, urosepsis, pyelonephritis, perineal necrosis, severe rash with fever, blisters, skin peeling, pain of oral/ocular mucous membranes, difficulty breathing, asthma, non-specific respiratory distress, liver abnormalities (jaundice) symptoms, sudden and severe headache, seizures, altered consciousness, visual disturbances, paralysis, significant decrease in urine output, severe generalized swelling, edema associated with increased blood pressure

Mild side effects

Hypoglycemia, constipation, itching, rash, increased urination, urination difficulties, increases in serum lipids on diagnostic tests, increased serum creatinine, decreased glomerular filtration rate, increased hematocrit, thirst, headache, orthostatic dizziness, sensory disturbances, drowsiness, facial paralysis, dizziness, memory disturbances, neuralgia, Parkinsonism, sensory impairment, drowsiness, peripheral edema, facial edema, fever, facial swelling, edema, vascular stent stenosis, vascular stenosis

The medication should be stored in a tightly sealed container to protect it from air and moisture, at a safe temperature between 1 and 30 degrees Celsius. Proper storage can help maintain the medication's efficacy for a longer period.

Appearance

Light yellow oblong film-coated tablet

Package unit

30 tablets/bottle